Integrated quantification method for protein measurements in clinical proteomics
Methods are provided for determining the expression level of target proteins in a subject. A plurality of respective peptide transitions are generated from a plurality of proteins obtained from a biological sample from the subject, wherein the plurality of proteins comprises both target and normalizing proteins. A mass spectroscopy (MS) signal intensity is measured from the plurality of respective peptide transitions and a plurality of corresponding stable isotope-labeled internal standard (SIS) peptide transitions. For each of the plurality of proteins, a response ratio is calculated between the MS signal intensity of the respective peptide transition and the corresponding SIS peptide transition. The response ratio for each target protein is normalized by a sample-dependent normalization factor calculated from the response ratio for each normalizing protein, wherein the normalized response ratios provide a determination of the expression level of the target proteins.
1. A method for determining the expression level of target proteins in a subject, comprising:
generating a plurality of respective peptide transitions from a plurality of proteins obtained from a biological sample from the subject, wherein the plurality of proteins comprises both target and normalizing proteins;
measuring a mass spectroscopy (MS) signal intensity from the respective plurality of peptide transitions and a plurality of corresponding stable isotope-labeled internal standard (SIS) peptide transitions;
for each of the plurality of proteins, calculating a response ratio between the MS signal intensity of the peptide transition and the corresponding SIS peptide transition;
calculating a sample-dependent normalization factor from the response ratios for the normalizing proteins; wherein the normalizing proteins are selected based on their ability to reduce intensity drift (D) of each of the plurality of respective peptide transitions, wherein intensity drift determines the deviation in abundance of each peptide transition from the overall median abundance of each peptide transition and
normalizing the response ratio for each target protein by the sample-dependent normalization factor, wherein the normalized response ratios provide a determination of the expression level of the target proteins.
2. The method of claim 1 , wherein the determination of the expression level of the target proteins provides a diagnosis of lung disease for the subject.
3. The method of claim 1 , wherein the normalizing proteins are selected based on their ability to reduce the median technical coefficient of variation (CV) of the plurality of proteins.
4. The method of claim 1 , wherein the plurality of proteins comprise at least two normalizing proteins selected from the group consisting of PEDF_HUMAN (Pigment epithelium-derived factor), MASP1_HUMAN (Mannan-binding lectin serine protease 1), GELS_HUMAN (Gelsolin), LUM_HUMAN (Lumican), C163A_HUMAN (Scavenger receptor cysteine-rich type 1 protein M130), and PTPRJ_HUMAN (Receptor-type tyrosine-protein phosphatase eta).
5. The method of claim 4 , wherein the plurality of proteins comprise six normalizing proteins including PEDF_HUMAN, MASP1_HUMAN, GELS_HUMAN, LUM_HUMAN, C163A_HUMAN, and PTPRJ_HUMAN.
6. The method of claim 5 , wherein the plurality of respective peptide transitions comprise LQSLFDSPDFSK (SEQ ID NO: 25) (692.34, 593.30), TGVITSPDFPNPYPK (SEQ ID NO: 26) (816.92, 258.10), TASDFITK (SEQ ID NO: 27) (441.73, 710.40), SLEDLQLTHNK (SEQ ID NO: 28) (433.23, 499.30), INPASLDK (SEQ ID NO: 29) (429.24, 630.30), and VITEPIPVSDLR (SEQ ID NO: 30) (669.89, 896.50).
7. The method of claim 1 , wherein the target proteins comprise at least five of KIT_HUMAN (Mast/stem cell growth factor receptor), FRIL_HUMAN (Ferritin light chain), COIA1_HUMAN (Collagen alpha-1(XVIII) chain), PRDX1_HUMAN (Peroxiredoxin-1), TENX_HUMAN (Tenascin-X), ENPL_HUMAN (Endoplasmin), GRP78_HUMAN (78 kDa glucose-regulated protein), BGH3_HUMAN (Transforming growth factor-beta-induced protein ig-h3), ALDOA_HUMAN (Fructose-bisphosphate aldolase A), GGH_HUMAN (Gamma-glutamyl hydrolase), CD14_HUMAN (Monocyte differentiation antigen CD14), LG3BP_HUMAN (Galectin-3-binding protein), TSP1_HUMAN (Thrombospondin-1), IBP3_HUMAN (Insulin-like growth factor-binding protein 3), TETN_HUMAN (Tetranectin), and ISLR_HUMAN (Immunoglobulin superfamily containing leucine-rich repeat protein).
8. The method of claim 7 , wherein the target proteins comprise ALDOA_HUMAN, FRIL_HUMAN, COIA1_HUMAN, LG3BP_HUMAN, and TSP1_HUMAN.
9. The method of claim 7 , wherein the target proteins comprise ALDOA_HUMAN, FRIL_HUMAN, KIT_HUMAN, GGH_HUMAN, and TSP1_HUMAN.
10. The method of claim 7 , wherein the target proteins comprise KIT_HUMAN, FRIL_HUMAN, COIA1_HUMAN, PRDX_HUMAN, TENX_HUMAN, ENPL_HUMAN, TENX_HUMAN, ENPL_HUMAN, GRP78_HUMAN, BGH3_HUMAN, ALDOA_HUMAN, GGH_HUMAN, CD14_HUMAN, LG3BP_HUMAN, IBP3_HUMAN, TETN_HUMAN, and ISLR_HUMAN.
11. The method of claim 1 , wherein the biological sample is selected from the group consisting of tissue, blood, plasma, serum, whole blood, urine, saliva, genital secretion, cerebrospinal fluid, sweat and excreta.
12. The method of claim 1 , wherein the plurality of proteins are obtained by immunoaffinity depletion.
13. The method of claim 12 , wherein the measuring step is performed by selected reaction monitoring mass spectrometry (SRM-MS).
14. The method of claim 1 , wherein the plurality of respective peptide transitions are generated by enzymatically digesting the plurality of proteins.
15. The method of claim 1 , wherein the response ratio (R) is defined as:
R p,s = A p,s / Â p,s
where A p,s is the peak area of the signal intensity of peptide transition p in the biological sample s, and  p,s is the peak area of the signal intensity the corresponding SIS peptide transition.
16. The method of claim 15 , wherein the normalized response ratio ({tilde over (R)}) is defined as:
{tilde over (R)} p,s =R p,s /S s I ,
where p is peptide transition, s is the biological sample, R p,s is the response ratio of peptide p in biological sample s, and S s I is the sample-dependent normalization factor.
17. The method of claim 1 , wherein the sample-dependent normalization factor (S) is defined as:
S
s
I
=
median
(
R
1
,
s
R
⋓
1
,
R
2
,
s
R
⋓
2
,
…
,
R
N
,
s
R
⋓
N
)
where S s I is the sample-dependent normalization factor calculated from the response ratios (R) of the N peptide transitions from normalizing proteins in the biological sample s, where R n,s is response ratio of peptide transitions from normalizing proteins n in the sample and {hacek over (R)} n is a scaling constant for the peptide normalizer that ensures values of {R n,s /{hacek over (R)} n } among all peptide transitions from normalizing proteins to be same on average.
18. The method of claim 1 , wherein intensity drift (D) is defined by:
D p,s =( I p,s −{hacek over (I)} p )/ {hacek over (I)} p
where p is peptide transition, s is the biological sample, I p,s is the abundance of peptide transition p in the sample s, and {hacek over (I)} p is the corresponding median value in all technical replica.
19. The method of claim 1 , wherein the plurality of respective peptide transitions and the plurality of corresponding stable isotope-labeled internal standard (SIS) peptide transitions are mixed together within a sample prior to the measuring step.
20. The method of claim 19 , wherein the determination of the expression level of the target proteins is independent of the volume of the sample.
21. The method of claim 1 , wherein the subject has a lung condition.
22. The method of claim 21 , wherein the lung condition is cancer or a non-cancerous lung condition.